Absolutely! It’s one of our major areas of interest including my labs :) the impetus is now on TIL in this space more than TCR tbh

Can’t speak for Iovance - I’m sure they gave multiple trials ongoing since the success of native TIL in melanoma- but in our branch we’re very much still working on old school expansion of native TIL (targeting neoag) in solid epithelial cancers.

The important conclusion is that bespoke TCR-T targeting private neoantigens CAN work (there was a prior study from PACT Biopharma with no responses). The goal is now to make this short term responses more durable. Lots of work ahead 3/3.

Several interesting correlates show up - most of the responses were in patients who have not received TIL targeting the same mutation, and targeting CD8 neoantigens. They were nevertheless not durable (unlike TIL in melanoma) 2/3

If it had an alternative initiation mutation even a driver p53 mutation is dispensable. we’ve seen a patient tumor responded to mutp53 T cells but then progressed with a wt p53 tumor (both tumors : initial and prog, had KRAS mut which is likely the driver) pretty mind boggling how much we don’t know

GoF p53 mutations have been prevalent in the field but there’s a recent study that has challenged this notion - might be of interest: aacrjournals.org/cancerdiscov...

Thank you !

Hello Jon - pls add me to this list thank you !

Hello can I pls be added - figuring this out- thank you so much.

🩺🦠🧪🔬 #Immunosky #Scisky

We report that anti tumor T cells in the blood are very low in frequency, but are apparently less dysfunctional, more stem-like relative to the SAME T cell clones within the tumor. We were able to develop a gene signature of blood derived T cells and predict TCRs from the blood of patients.

Thank you for the kind words 🙏🏽

Here is the direct link to the postdoc positions: pls contact if interested here and elsewhere. ccr.cancer.gov/careers/post...